HALO.US Halozyme Therapeutics Inc

Healthcare Biotechnology USA Stocks
100.27 USD
Close of Nov 15, 2026
61.23 134.00
Market cap
USD 11.4B
P/E
25.1x
P/B
97.15x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HALO.US undervalued?

Graham number

The Graham number of Halozyme Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Halozyme Therapeutics Inc fundamental analysis

No fundamental analysis for Halozyme Therapeutics Inc yet.

Halozyme Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombin…

Full company profile